BR0311952A - New compounds useful for treating obesity, type ii diabetes and snc disorders - Google Patents

New compounds useful for treating obesity, type ii diabetes and snc disorders

Info

Publication number
BR0311952A
BR0311952A BR0311952-1A BR0311952A BR0311952A BR 0311952 A BR0311952 A BR 0311952A BR 0311952 A BR0311952 A BR 0311952A BR 0311952 A BR0311952 A BR 0311952A
Authority
BR
Brazil
Prior art keywords
diabetes
type
compounds useful
new compounds
treating obesity
Prior art date
Application number
BR0311952-1A
Other languages
Portuguese (pt)
Inventor
Johansson
Gary
Jenmalm-Jensen
Annika
Beierlein
Katarina
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/en
Priority claimed from SE0202181A external-priority patent/SE0202181D0/en
Priority claimed from SE0202908A external-priority patent/SE0202908D0/en
Priority claimed from SE0300357A external-priority patent/SE0300357D0/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of BR0311952A publication Critical patent/BR0311952A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"NOVOS COMPOSTOS úTEIS PARA O TRATAMENTO DE OBESIDADE, DIABETES TIPO II E DISTúRBIOS DO SNC". A presente invenção refere-se e compostos de fórmula geral (I) onde P é sulfona ou sulfonamida e A, B, W, X, Y e ^ R3^ são como definidos no relatório descritivo, a composições farmacêuticas compreendendo estes compostos, e ao uso dos compostos para a profilaxia e tratamento de condições médicas relativas à obesidade, diabetes do tipo II, e/ou distúrbios do SNC, para obter-se redução do peso corporal e do ganho de peso corporal."NEW USEFUL COMPOUNDS FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS". The present invention relates to and compounds of formula (I) wherein P is sulfone or sulfonamide and A, B, W, X, Y and R 3 are as defined in the specification, pharmaceutical compositions comprising these compounds, and the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and / or CNS disorders to achieve reduction in body weight and body weight gain.

BR0311952-1A 2002-06-20 2003-06-19 New compounds useful for treating obesity, type ii diabetes and snc disorders BR0311952A (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (en) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (en) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (en) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (en) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
BR0311952A true BR0311952A (en) 2005-04-19

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311952-1A BR0311952A (en) 2002-06-20 2003-06-19 New compounds useful for treating obesity, type ii diabetes and snc disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (en)
CN (1) CN1662521A (en)
AU (1) AU2003243091A1 (en)
BR (1) BR0311952A (en)
CA (1) CA2486989A1 (en)
EA (2) EA008835B1 (en)
IL (1) IL165051A0 (en)
MX (1) MXPA04012914A (en)
NO (1) NO20050294L (en)
NZ (3) NZ536600A (en)
RS (1) RS111204A (en)
SG (1) SG156524A1 (en)
WO (1) WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
SE0301446D0 (en) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
CN1826322B (en) 2003-07-22 2012-04-18 艾尼纳制药公司 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related therto
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
EA010298B1 (en) * 2003-12-19 2008-08-29 Биовитрум Аб (Пабл) Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-htreceptor-related disorder
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
EP1737845A4 (en) * 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp Disalt inhibitors of il-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) * 2005-05-23 2007-05-30 Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) * 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
JP2008545008A (en) * 2005-06-30 2008-12-11 プロシディオン・リミテッド GPCR agonist
ES2513165T3 (en) 2005-10-07 2014-10-24 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol-3-kinase inhibitors
BRPI0618206A2 (en) 2005-11-03 2011-08-23 Hoffmann La Roche chromosyl arylsulfonyl as 5-ht6 inhibitors as well as pharmaceutical composition, use and process for producing them
AR058705A1 (en) 2005-12-23 2008-02-20 Astrazeneca Ab BENCIMIDAZOL COMPOUNDS AS VANILOID 1 RECEIVER INHIBITORS (VR1)
MX2008015843A (en) 2006-06-20 2009-01-09 Hoffmann La Roche Tetralin and indane derivatives and uses thereof.
CA2655524A1 (en) 2006-06-20 2007-12-27 F. Hoffman-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
EP2041079A1 (en) 2006-06-20 2009-04-01 F. Hoffmann-Roche AG Arylsulfonyl naphthalene derivatives and uses thereof
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst New benzimidazole derivatives 290
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JP5872027B2 (en) * 2011-05-09 2016-03-01 フォーマ ティーエム， エルエルシー． Piperidine derivatives and compositions for inhibiting nicotinamide phosphoribosyltransferase (NAMPT)
CN104725295B (en) 2013-12-20 2019-05-24 广东东阳光药业有限公司 Aromatic heterocyclic derivatives and its application on drug
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (en) 2015-07-15 2017-06-16 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
AU6391894A (en) * 1993-03-16 1994-10-11 Pfizer Inc. Naphthalene derivatives
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
AU2001264566A1 (en) * 2000-05-05 2001-11-20 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
AU2001259707A1 (en) * 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
EP1406884A1 (en) * 2001-05-11 2004-04-14 Biovitrum Ab Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
SK16052003A3 (en) * 2001-06-07 2004-10-05 Hoffmann La Roche New indole derivatives with 5-HT6 receptor affinity
US7144883B2 (en) * 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds

Also Published As

Publication number Publication date
RS111204A (en) 2006-12-15
IL165051A0 (en) 2005-12-18
AU2003243091A1 (en) 2004-01-06
WO2004000828A1 (en) 2003-12-31
EP1513828A1 (en) 2005-03-16
EA200500054A1 (en) 2005-06-30
CN1662521A (en) 2005-08-31
NO20050294L (en) 2005-02-04
CA2486989A1 (en) 2003-12-31
EA200600975A1 (en) 2006-10-27
EA008835B1 (en) 2007-08-31
NZ552282A (en) 2008-07-31
NZ536600A (en) 2007-08-31
NZ552283A (en) 2008-07-31
EA011581B1 (en) 2009-04-28
MXPA04012914A (en) 2005-03-31
SG156524A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
BR0311952A (en) New compounds useful for treating obesity, type ii diabetes and snc disorders
DE60013250D1 (en) Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
RU2325389C2 (en) Composition and derivatives of substituted azaindoloxoacetapiperazine characterized by antiviral activity
BRPI0409227B8 (en) "compound, pharmaceutical composition, use of a compound and process for the preparation of a compound of formula (i)"
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
WO2004067550A3 (en) Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
SE0403006D0 (en) New compounds
BRPI0418099A (en) compounds, pharmaceutical composition, and use of a compound
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
ATE385419T1 (en) DERMATOLOGICAL AND COSMETIC COMPOSITIONS CONTAINING A FURFURYL DERIVATIVE
ATE384058T1 (en) THIAZOLE DERIVATIVES
NO20052699L (en) 4 (phenylpiperazinylmethyl) benzamide derivatives and their use in the treatment of pain and gastrointestinal disorders.
EA200600971A1 (en) APPLICATION OF SUBSTITUTED 2 - AMINOTHETRALINES FOR THE PREVENTION TREATMENT OF PARKINSON'S Disease
WO2022238565A3 (en) Modulators of sortilin activity
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
DE60233350D1 (en) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
CY1109950T1 (en) NEW PRODUCTS OF 4,4-DYPHYTHODES- (3-AMINOBUTANIUM-1-SULPHONIC) AND COMPOSITIONS CONTAINING THEM
SE0303480D0 (en) Benzofuranes
DE602004015089D1 (en) PYRROLOIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THESE INGREDIENT COMPOSITIONS, AND THEIR USE AS NOOTROPIKA
EA200601687A1 (en) Tetrahydroisoquinoline TETRAGIDROBENZAZEPINOVYE AND DERIVATIVES (OPTIONS), pharmaceutical compositions and pharmaceutical kits, medicinal and reference instruments for the test-systems based on them, methods of treatment and prevention of diseases in which the down-regulation of a favorable or inhibiting the expression or function of IGF-1 Receptor
BRPI0413684A (en) compounds, pharmaceutical composition and methods of preparation, treatment of microbial infection and extermination of microorganism and uses
BRPI0410657A (en) compound, pharmaceutical composition, use of a compound, method for treating a disorder of a patient, and process for preparing a compound
TW200510354A (en) Benzoxazinone-derived sulphonamide compounds, their preparation and use as medicaments
DE602006017855D1 (en) USE OF N- (DIBENZ (B, F) OXEPIN-10-YLMETHYL) -N-METHYL-N-PROP-2-INYLAMINE (OMIGAPIL) FOR PROPHYLAXIS AND / OR TREATMENT OF MUSCLE DYSTROPHY

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOVITRUM AB (PUBL) (SE)

Free format text: ALTERADO DE: BIOVITRUM AB

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 207/12, C07D 211/40, C07D 211/46, C07D 215/46, C07D 217/22, C07D 401/04, C07D 406/12, C07D 471/04, C07D 495/04, A61K 31/40, A61K 31/4025, A61K 31/4353, A61K 31/4465, A61K 31/4523, A61K 31/496, A61K 31/551, A61P 25/00, A61P 3/04, A61P 3/10, A61P 3/00, A61P 43/00

Ipc: C07D 401/04 (2011.01), C07D 495/04 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.